ONCOLYTICS BIOTECH INC

Oncolytics Biotech is a clinical-stage biopharmaceutical enterprise focused on developing pelareorep, an intravenously administered immunotherapeutic candidate. Pelareorep is a proprietary isolate of reovirus designed to replicate selectively inside RAS-mutated tumor cells, stimulate innate and adaptive immune defenses, and transform the immunosuppressive microenvironment of solid tumors. The firm prioritizes platform development for gastrointestinal malignancies—including pancreatic ductal adenocarcinoma, anal canal carcinoma, and metastatic colorectal cancer—alongside clinical evaluations in breast cancer. These investigational programs aim to improve clinical responses when paired with chemotherapy or checkpoint inhibitors. Target beneficiaries comprise oncology patients who have exhausted or derived minimal benefit from current standard cancer therapies.

The enterprise conducts its research programs internationally across multiple jurisdictions, utilizing external study sites and clinical collaborations throughout North America. It manages a portfolio of 137 patents spanning the United States, Canada, and other foreign regions. Manufacturing operations rely principally on a single toll manufacturer located within the United States to supply clinical-grade active ingredients and formulated drug products. The provided text contains no details disclosing the company's corporate headquarters location.

Summary of the business section of Oncolytics Biotech's latest annual report, written by StockData.

“As of December 31, 2025, we had 29 total and full-time employees.”